An interventional study of Pomegranate seed powder in Metabolic Syndrome, sponsored by Asif Ali. Recruiting at 1 site in Pakistan. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-07-13.
Sponsored by Asif Ali · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 12th largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 5th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 18–45
Hamdard University · Sites in Pakistan
Ages 35–65
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–50
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–55
University of Lahore · Sites in Pakistan
Ages 18–60
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 60 across the 16 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 9 most frequent:
This is the only study on the registry with Asif Ali as lead sponsor.
Asif Ali has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Metabolic syndrome is a public health concern worldwide and in Pakistan as well. Abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol are its hallmarks while pomegranate seed's unique chemical composition has sparked research into the health benefits in same arena as weight control, blood lipid profile changes, and other metabolic disturbances. It's high time to study therapeutic efficiency of Pomegranate seed powder against metabolic syndrome.
Metabolic syndrome, accumulation of certain metabolic risk factors, such as abdominal obesity, hyperglycemia, hypertriglyceridemia, hypertension, and low HDL cholesterol, has been noted as one of the most important risk factors for the epidemic of type 2 diabetes and cardiovascular disease in the 21st century. It has become a significant public health concern and a global epidemic with a prevalence rate of about 25% among American adults. Multiple researches have demonstrated the effectiveness of pomegranate in the management of diabetes, inflammatory conditions, obesity, and blood lipid levels, and consequently metabolic syndrome. Various pomegranate components have the potential to substitute anti-diabetic medications as well Pomegranate seed's unique chemical composition has sparked research into the health benefits, such as weight control, blood lipid profile changes, and other metabolic disorders.
seed powder can influence the patient's metabolic syndrome-related indicators.
Hypothesis:
Pomegranate seed powder can be effective to treat the individuals with impaired metabolism.
Methodology:
In a clinical trial, patients of metabolic syndrome (n=50) will be given pomegranate seed powder dose for over 8 weeks, twice a day. Biochemical outcomes including blood pressure, FBG, cholesterol, hemoglobin level will be determined before and after the completion of trial in addition to patient's weight. Finally, using one-way ANOVA and T-test, collected data will be analyzed.
Expected outcome: The study will explore the potential of pomegranate seed powder in treating metabolic syndrome's risk factors. Therefore, our findings on the studied parameters of patient will assist future researchers in developing tested, evidence-based recommendations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pomegranate seed powder is administered for alleviating symptoms of metabolic syndrome
Dietary Supplement: Pomegranate seed powder
10 g powder / day
Also known as: Punica granatum
Lipid Profile
The change in Lipid Profile, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
Time frame: 7 weeks
Fasting Glucose
The change in Blood Glucose level, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
Time frame: 7 weeks
Blood Pressure
The change in both systolic and diastolic blood pressure after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
Time frame: 7 weeks
Weight
The change in weight, after consuming Pomegranate seed powder for 7 weeks will be assessed, to look for improvements.
Time frame: 7 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Intervention study, data will be confidential to maintain patients privacy, enrollment of patients with their consent
Started Feb 2023 (actual). Primary completion is estimated for Jul 2023, 5 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 5 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.